Details of the Drug
General Information of Drug (ID: DMJ2PG1)
Drug Name |
VTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
CHEMBL525571; alpha-Cgrp (8-37); Val(8)-phe(37)-cgrp; CGRP8-37; CGRP-(8-37); Calcitonin gene-related peptide (8-37); h alpha-CGRP8-37; 8-Val-37-phe-calcitonin gene-related peptide; Calcitonin gene-related peptide, val(8)-phe(37)-; Calcitonin gene-related peptide, valyl(8)-phenylalanine(37)-; BDBM50000743; NCGC00167246-01; CALCITONIN GENE RELATED PEPTIDE (8-37); [Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2] hC; alpha-Calcitonin gene-r
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 5 | Molecular Weight (mw) | 3125.6 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -9.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 104 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 47 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 44 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||